About SiNON
SiNON is a company based in Durham (United States) founded in 2015 by Afreen Allam. SiNON offers products and services including Carbon Nanoparticle (CNP) Technology. SiNON operates in a competitive market with competitors including Impel NeuroPharma, CraniUS, Cognos Therapeutics, Bionxt and NsGene, among others.
- Headquarter Durham, United States
- Founders Afreen Allam
- SectorsHealthcare
- Website sinontx.com
- Social LinkedIn
Products & Services of SiNON
SiNON offers a comprehensive portfolio of products and services, including Carbon Nanoparticle (CNP) Technology.
Enables targeted drug transport across blood-brain barrier with reduced toxicity.
People of SiNON
1 people are tracked at SiNON (1 in leadership).
| Name | Role | Group |
|---|---|---|
Afreen Allam | Founder & CEO | Leadership |
Complete people profiles for SiNON
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Competitors of SiNON
SiNON operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Impel NeuroPharma, CraniUS, Cognos Therapeutics, Bionxt and NsGene, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| craniustherapeutics.com | 2021 | Baltimore, United States | $20.5M | – | Drug delivery systems for brain diseases and disorders are developed. | |
| cognosthx.com | 2015 | Los Angeles, United States | $5.75M | 13 | Cognos Therapeutics is focused on innovative neurological and oncological treatments. | |
| bionxt.com | 2018 | Vancouver, Canada | – | 49 | Drug formulations and delivery systems for diseases are developed. | |
| nsgene.dk | 1999 | Ballerup, Denmark | $5.14M | – | Specializes in drug delivery systems and therapeutics for central nervous system diseases. | |
| cordancemedical.com | 2018 | Mountain View, United States | – | – | Non-invasive ultrasound device for blood-brain barrier is developed. | |
| passport-tech.com | 2019 | San Diego, United States | – | – | Transdermal drug delivery systems are developed using microporation technology. | |
| palyonmedical.com | 2004 | New York, United States | $24M | – | Develops implantable drug delivery systems for central nervous system disorders. | |
| neurochase.com | 2020 | Cardiff, United Kingdom | – | 4 | Provides targeted CNS therapy delivery and consultancy for pharma and biotech industries. |
Detailed competitors of SiNON
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SiNON
The website of SiNON (sinontx.com) receives about 2.7K visits a month.
- Monthly visits2.7K
▲ 17.2% vs previous month
Similar companies to SiNON
10 companies that operate in the same segment as SiNON (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SiNON
SiNON was founded in 2015.
SiNON is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Afreen Allam is the current CEO of SiNON. They have also founded this company.
SiNON has developed a patented nanoparticle-based drug delivery system to transport drugs to treat neurological diseases. The company has developed Carbon Nano Dot, which is a drug encapsulation system made of non-metal compound carbon with a hollow center to deliver the drugs by crossing the blood-brain barrier by attaching chemical functional groups to the surface of the capsule.
SiNON's top competitors include Impel NeuroPharma, CraniUS and Cognos Therapeutics.
SiNON offers Carbon Nanoparticle (CNP) Technology.